Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
NCT07621159 HDM-2017 Advanced Colorectal Adenocarcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07621159 HDM-2017 Advanced Colorectal Adenocarcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
NCT07621159 clinical trial report covering HDM-2017, Phase 1/2, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07622940 Fludarabine Phosphate Adenocarcinoma of Esophagus Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07622940 Fludarabine Phosphate Adenocarcinoma of Esophagus Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
NCT07622940 clinical trial report covering Fludarabine Phosphate, Phase 1/2, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07623486 HSK-44459 Plaque psoriasis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07623486 HSK-44459 Plaque psoriasis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
NCT07623486 clinical trial report covering HSK-44459, Phase 1/2, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07622225 Enlonstobart Advanced Malignant Solid Neoplasm Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07622225 Enlonstobart Advanced Malignant Solid Neoplasm Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
NCT07622225 clinical trial report covering Enlonstobart, Phase 1/2, endpoints, sponsor, geography, readout timing and development white space.
Read →
JPRN-jRCT2031260191 CMG1A46 B-cell lymphoma refractory Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
JPRN-jRCT2031260191 CMG1A46 B-cell lymphoma refractory Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
JPRN-jRCT2031260191 clinical trial report covering CMG1A46, Phase 1/2, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07623525 DIAG-723 Pulmonary Arterial Hypertension Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07623525 DIAG-723 Pulmonary Arterial Hypertension Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
NCT07623525 clinical trial report covering DIAG-723, Phase 1/2, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07623707 B-901 Locally Advanced Malignant Solid Neoplasm Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07623707 B-901 Locally Advanced Malignant Solid Neoplasm Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
NCT07623707 clinical trial report covering B-901, Phase 1/2, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07623356 Carboplatin Advanced Lung Non-Small Cell Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07623356 Carboplatin Advanced Lung Non-Small Cell Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
NCT07623356 clinical trial report covering Carboplatin, Phase 1/2, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07624227 Xanomeline Tartrate/Trospium Chloride Systemic Carnitine Deficiency Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07624227 Xanomeline Tartrate/Trospium Chloride Systemic Carnitine Deficiency Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
NCT07624227 clinical trial report covering Xanomeline Tartrate/Trospium Chloride, Phase 1/2, endpoints, sponsor, geography, readout timing and development
Read →
CTR20262182 IMM-040811 Advanced Malignant Solid Neoplasm Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
CTR20262182 IMM-040811 Advanced Malignant Solid Neoplasm Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
CTR20262182 clinical trial report covering IMM-040811, Phase 1/2, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07627698 Fludarabine Phosphate Uveal Melanoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07627698 Fludarabine Phosphate Uveal Melanoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
NCT07627698 clinical trial report covering Fludarabine Phosphate, Phase 1/2, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07627971 SKY-GJB2 (Skylark Bio) Deafness, Autosomal Recessive 1A Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07627971 SKY-GJB2 (Skylark Bio) Deafness, Autosomal Recessive 1A Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
NCT07627971 clinical trial report covering SKY-GJB2 (Skylark Bio), Phase 1/2, endpoints, sponsor, geography, readout timing and development white space.
Read →